Paper32916539
Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target.
Li Y and 3 others. Biomed Pharmacother, 2020. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target. Papers, record 32916539. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32916539
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Monoamine Oxidase | Major topic |
| Animals | |
| Coronary Artery Disease | |
| Heart Failure | |
| Humans | |
| Hypertension |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41629438 | Cardiovascular risk assessed using the SCORE system and blood renalase concentration in the Polish subpopulation of the PURE study. | Sci Rep | 2026 | https://conductscience.org/library/papers/41629438 | PubMed |
| 41495987 | Renalase stimulates aldosterone production via PMCA4b/cAMP in NCI-H295R cells. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/41495987 | PubMed |
| 41477152 | Frailty as an independent predictor of one-year outcomes in patients with HFpEF after acute myocardial infarction: insights from a multicenter retrospective cohort in China. | J Geriatr Cardiol | 2025 | https://conductscience.org/library/papers/41477152 | PubMed |
| 41314850 | Association between periprocedural change in serum renalase and microvascular obstruction in patients with STEMI after primary percutaneous coronary intervention: protocol for the ReMVOS prospective cohort study. | BMJ Open | 2025 | https://conductscience.org/library/papers/41314850 | PubMed |
| 40739379 | Renal Denervation Improves Myocardial Mitochondrial Dysfunction and Myocardial Fibrosis by Inhibiting the NE/KLF15/renalase Pathway. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/40739379 | PubMed |
| 40253324 | Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients. | BMC Nephrol | 2025 | https://conductscience.org/library/papers/40253324 | PubMed |
| 39200179 | Renalase Potential as a Marker and Therapeutic Target in Chronic Kidney Disease. | Biomedicines | 2024 | https://conductscience.org/library/papers/39200179 | PubMed |
| 38068986 | Coexistence of Cardiovascular Risk Factors and Blood Renalase Concentration. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38068986 | PubMed |
| 37905164 | Association Between Renalase Gene Polymorphism (rs2296545) and Hypertension in Egyptian Chronic Kidney Disease Patients. | Cureus | 2023 | https://conductscience.org/library/papers/37905164 | PubMed |
| 37371077 | The Multi-Faceted Nature of Renalase for Mitochondrial Dysfunction Improvement in Cardiac Disease. | Cells | 2023 | https://conductscience.org/library/papers/37371077 | PubMed |
| 37048331 | Exploring the Potential Medicinal Benefits of Ganoderma lucidum: From Metabolic Disorders to Coronavirus Infections. | Foods | 2023 | https://conductscience.org/library/papers/37048331 | PubMed |
| 35941358 | Renalase: a novel regulator of cardiometabolic and renal diseases. | Hypertens Res | 2022 | https://conductscience.org/library/papers/35941358 | PubMed |
| 35898283 | Aerobic Exercise Training Improves Renal Injury in Spontaneously Hypertensive Rats by Increasing Renalase Expression in Medulla. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35898283 | PubMed |
| 35711341 | The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35711341 | PubMed |
| 35125818 | Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. | World J Gastroenterol | 2022 | https://conductscience.org/library/papers/35125818 | PubMed |
| 34680147 | Elevated Levels of Renalase, the β-NAD(P)H Isomerase, Can Be Used as Risk Factors of Major Adverse Cardiovascular Events and All-Cause Death in Patients with Chronic Kidney Disease. | Biomolecules | 2021 | https://conductscience.org/library/papers/34680147 | PubMed |
| 34395559 | The Discriminatory Ability of Renalase and Biomarkers of Cardiac Remodeling for the Prediction of Ischemia in Chronic Heart Failure Patients With the Regard to the Ejection Fraction. | Front Cardiovasc Med | 2021 | https://conductscience.org/library/papers/34395559 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| RNLS | 55328 | PubTator's text mining | https://conductscience.org/library/genes/55328 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32916539
GET https://conductscience.org/api/papers/v1/32916539/authors